行情

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

实时行情|Nasdaq Last Sale

1.790
+0.010
+0.56%
已收盘, 16:00 04/02 EDT
开盘
1.860
昨收
1.780
最高
1.880
最低
1.730
成交量
7.83万
成交额
--
52周最高
4.230
52周最低
1.230
市值
1.17亿
市盈率(TTM)
-2.8848
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VTVT价格均价为7.00,最高价位8.00,最低价为6.00。

EPS

VTVT 新闻

更多
  • 全球抗疫:要么一荣俱荣,要么全盘皆输
  • 新浪财经 · 27分钟前
  • 瑞幸承认财务造假的资本前戏:黎辉减持回本,刘二海一股没卖
  • 澎湃新闻 · 39分钟前
  • “50美分”交易员狂赚4亿美元后,将目标转向黄金
  • 新浪财经综合 · 54分钟前
  • 当两个明斯基过程遭遇大幅冲击:美国企业面临大考
  • 新浪财经-自媒体综合 · 56分钟前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

VTVT 简况

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
展开

微牛提供vTv Therapeutics Inc(NASDAQ-VTVT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VTVT股票新闻,以帮助您做出投资决策。